Last updated: April 12, 2024
Sponsor: Bioprojet
Overall Status: Active - Recruiting
Phase
2
Condition
Bulimia
Binge Eating Disorder
Treatment
BP1.4979 active drug
Placebo
Clinical Study ID
NCT05118906
P20-08 / BP1.4979
2021-000472-11
Ages 18-65 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patient must voluntarily express a willingness to participate in this study, sign anddate an informed consent prior to beginning any protocol required procedures.
- Female aged between 18 and 65 years, inclusive.
- Diagnosis of BED according to DSM-5 criteria
- BMI < 50 kg/m2.
Exclusion
Exclusion Criteria:
- Current diagnosis of bulimia nervosa or anorexia nervosa.
- History of bariatric surgery.
- Patient who is pregnant, lactating, or of childbearing potential who is not usingadequate contraceptive measures. The following are considered adequate methods ofbirth control: 1. intrauterine device (IUD); 2. barrier protection; 3. contraceptiveimplantation system; 4. oral contraceptive pills; 5. surgically sterile patient; and
- abstinence. All participants should have a negative pregnancy test prior torandomization
- Ongoing alcohol or tobacco addiction treatment (except Nicotine Replacement Therapy [NRT] with at least one-month stable dose prior to screening visit).
Study Design
Total Participants: 66
Treatment Group(s): 2
Primary Treatment: BP1.4979 active drug
Phase: 2
Study Start date:
March 07, 2022
Estimated Completion Date:
March 31, 2025
Study Description
Connect with a study center
Nutrition Department, La Pitié Salpêtrière Hospital
Paris, 75013
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.